|
| 1 |
|
Conditions listed in this trial |
|
|
Melanoma (Skin) |
|
|
Neuroblastoma |
|
|
Sarcoma |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Melanoma |
|
| 3 |
|
More general conditions related to this trial |
|
|
Neoplasms |
|
|
Neoplasms by Histologic Type |
|
|
Neoplasms, Connective and Soft Tissue |
|
|
Neoplasms, Germ Cell and Embryonal |
|
|
Neoplasms, Glandular and Epithelial |
|
|
Neoplasms, Nerve Tissue |
|
|
Neoplasms, Neuroepithelial |
|
|
Neuroectodermal Tumors |
|
|
Neuroectodermal Tumors, Primitive |
|
|
Neuroectodermal Tumors, Primitive, Peripheral |
|
|
Neuroendocrine Tumors |
|
|
Nevi and Melanomas |
|
| 4 |
|
Interventions listed in this trial |
|
|
hu14.18-IL2 fusion protein |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Antibodies, Monoclonal |
|
|
Interleukin-2 |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Analgesics |
|
|
Analgesics, Non-Narcotic |
|
|
Antineoplastic Agents |
|
|
Central Nervous System Agents |
|
|
Immunologic Factors |
|
|
Peripheral Nervous System Agents |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
|
Sensory System Agents |
|
|
Therapeutic Uses |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Children's Oncology Group |
|
|
National Cancer Institute (NCI) |
